Introduction {#sec1}
============

Soft tissue sarcomas (STSs) are an assorted pool of solid tumors categorized together due to their clinical and histopathological features ([@ref7]; [@ref3]). STSs represent approximately 15% of all canine skin cancers, with a yearly incidence of 35 cases per 100,000 patients at risk ([@ref11]). These tumors usually present as soft or firm masses with poorly defined margins and frequent infiltration of the neighboring tissues ([@ref6]). Therefore, conservative surgery is unable to achieve a complete eradication of the tumor, thus frequently resulting in recurrence ([@ref12]). Some prognostic factors for recurrence have been identified, such as incompleteness of resection versus radical excision ([@ref4]), or tumor grade ([@ref3]). Hematological dissemination is a common event, being observed in up to 20% of cases ([@ref11]). Response to chemotherapy and radiation therapy is mostly limited to neoplasms smaller than 5 cm in diameter ([@ref11]). The most commonly adopted strategies aimed at increasing local control involved the combination of surgery with adjuvant therapies, such as radiation therapy ([@ref8]; [@ref13]), sometimes associated with hyperthermia ([@ref29]), adjuvant chemotherapy ([@ref15]), and electrochemotherapy (ECT) ([@ref19], [@ref20], [@ref23]). ECT is an anticancer therapy that couples the administration of chemotherapy agents with the delivery of trains of permeabilizing electric pulses having an appropriate waveform ([@ref24], [@ref25], [@ref26]). These pulses induce transient perturbation and rearrangement of the cell membrane, resulting in increased cross-flow of material through the cytoplasmic membrane, including low permeant molecules, such as bleomycin and cisplatin ([@ref17]). Direct electrical destruction of cells is a negligible effect, caused by the inability of some cells to sequester calcium within the sarcoplasmic reticulum ([@ref17]). The improved chemotherapy uptake by cancer cells induces tumor apoptotic death ([@ref17]). Local cisplatin has been used to increase local control with good results, especially for grade I and II STS ([@ref2]). Nevertheless, since the first ECT studies, it has been shown that electroporation greatly increases the efficacy of cisplatin, compared to controls treated with cisplatin alone ([@ref16]; [@ref30]). Several studies have been investigating ECT for the treatment of STS in pets showing that it was a useful addition to surgery ([@ref20], [@ref21], [@ref23]). In this study, we evaluated the tolerability and effectiveness of a combined ECT protocol involving local and systemic administration of chemotherapy agents (cisplatin and bleomycin, respectively) in dogs carrying incompletely excised STS.

Materials and Methods {#sec2}
=====================

Thirty-three dogs with histopathologically confirmed, incompletely excised sarcomas were referred for adjuvant ECT. A patient present with a large grade II peripheral nerve sheath tumor of the left foreleg was shown in [Figure 1A](#fig1){ref-type="fig"}. Patients, staged according to the World Health Organization (WHO) grading system, were treated if they fulfilled the following criteria: i) accessibility of the neoplasm location; ii) absence of distant metastases; iii) absence of other life-threatening diseases such as cardiac disease and renal failure; and iv) absence of bone involvement. Patients were staged through the measurement of the surgical field, histopathological exam of tumor, regional lymph node fine-needle aspiration biopsy (when feasible), complete blood cell count, chemistry profile, urinalysis, chest radiographs, and abdominal ultrasonography. Canine patients received two sessions of ECT 2 weeks apart, starting at the time of suture removal (10--14 d after surgery). Dogs were pre-medicated with acepromazine, butorphanol, and medetomidine, followed by propofol to effect. Bleomycin was intravenously injected as a bolus at the dose of 20 mg/m^2^. Moreover, aiming at improving local control, the tumor bed (a surface of two centimeters deep under the surgical scar, or in case of leg location, as deep as feasible and two additional centimeters of margins at each side), was infiltrated with cisplatin at the dose of 0.5 mg/cm^2^. Five minutes after the chemotherapy injections, sequences of eight biphasic pulses lasting 50 + 50 μsec each, were delivered in bursts of 1,300 V/cm using caliper electrodes until the treatment coverage was achieved as elsewhere described ([@ref23]). An application of plate electrodes on the tumor bed of a patient is shown in [Figure 1B](#fig1){ref-type="fig"}. Pulses were generated using an electroporator certified for veterinary use (Onkodisruptor^®^) (. 1C). Contact between the patients and the electrodes was optimized using an electroconductive gel. The treatment was repeated after 2 weeks. During the ECT sessions, the patients were monitored using a cardiac monitor and pulse oximeter.

Results {#sec3}
=======

Thirty-three patients were referred for adjuvant treatment over a period of 4 yr. Three dogs were lost to follow-up, leaving 30 patients for statistical analysis. Specifically, the remaining dogs belonged to the following breeds: 20 mixed breed dogs, one Rottweiler, one Beagle, one dobermann, one bulldog, one hunting dog, one German shepherd, two dachshunds, and two Abruzzese shepherd. Age varied from 3 to 14 yr with a median of 10 yr. Tumor histotypes were the following: nine perivascular wall tumors, six peripheral nerve sheath tumors, six fibrosarcomas, three chondrosarcomas, two hemangiosarcomas, two liposarcomas, and two undifferentiated sarcomas. The histological features of a peripheral nerve sheath tumor are depicted in [Figure 1D](#fig1){ref-type="fig"}. Patients characteristics including histological grade and site of the tumour are summarized in [Table 1](#table1){ref-type="table"}. The treatment was well tolerated and side effects were confined to local inflammation in three dogs that were controlled through the administration of an anti-inflammatory drug (firocoxib as per manufacturer's instructions). Systemic side effects were not identified. In terms of response, twenty-six dogs (86.6%) had no evidence of recurrence at different times ([Table 1](#table1){ref-type="table"}), four had recurrence, and one of the four recurring dogs (affected by hemangiosarcoma) died of lung metastases ([Table 1](#table1){ref-type="table"}). Two of the twenty-six responders died of unrelated causes at different times. Median disease free was not reached at the time of writing: the Kaplan--Meier estimated disease free of 857 d for all the canine population ([Fig. 2A](#fig2){ref-type="fig"}). In the attempt to identify prognostic factors, a comparison between the larger cohort of tumors (perivascular wall tumors) versus all the other tumor histotypes was performed since they are also considered the best responders to therapy ([@ref27]; [@ref1]). Again, median disease free was not reached and the calculated estimated disease free values were: 1,162 d versus 992, respectively (*p*= 0.222) ([Fig. 2B](#fig2){ref-type="fig"}).

![(A) A dog with a large grade II peripheral nerve sheath tumor of the left foreleg at the presentation. (B) Permeabilizing electric pulses are administered using plate electrodes. (C) The electroporator used for the therapies. (D) The histopathology of the tumor showing the typical alternating Antoni A and B areas (Hematoxylin and Eosin; original magnification ×10).](OpenVetJ-9-88-g001){#fig1}

###### Patients' characteristics and outcome.

  Age (Years)   Tumor site      T stage   Histotype        Disease free\*   Outcome
  ------------- --------------- --------- ---------------- ---------------- ------------------------
  8 1/2         Left foreleg    T3        PWT Grade II     483              NED
  13            Right foreleg   T3        U-SA             93               Recurrence, euthanasia
  2 1/2         Right hindleg   T2        HSA              1053             NED
  9             Head            T3        PNST Grade II    1505             NED
  8             Thorax          T3        FSA Grade II     1249             NED
  9             Right foreleg   T2        PWT Grade I      1298             NED
  10            Left foreleg    T2        PWT Grade II     1235             NED
  3             Right foreleg   T3        U-SA             366              Recurrence, amputation
  4             Abdomen         T3        CSA              856              Dead, renal failure
  10            Lumbar          T3        PWT Grade II     840              NED
  10 1/2        Head            T2        HSA              366              Recurrence,metastasis
  10            Right hindleg   T3        LipoSA           443              Recurrence, amputation
  8             Left hindleg    T3        PWT Grade II     692              NED
  6             Right foreleg   T2        PWT Grade II     660              NED
  14            Thorax          T3        PNST Grade II    413              Dead, cardiac disease
  4             Flank           T3        LipoSA           604              NED
  6             Flank           T3        FSA Grade II     574              NED
  13 1/2        Head            T2        CSA              513              NED
  10            Left hindleg    T2        PWT Grade II     370              NED
  13            Perineum        T2        FSA Grade II     370              NED
  7             Perineum        T3        FSA Grade II     338              NED
  8             Flank           T3        CSA              286              NED
  10            Right foreleg   T3        PNST Grade III   283              NED
  11            Left foreleg    T2        PNST Grade II    269              NED
  10            Abdomen         T3        PNST Grade II    584              NED
  3             Flank           T3        FSA Grade II     212              NED
  6             Right foreleg   T2        PWT Grade II     209              NED
  5             Left foreleg    T2        FSA Grade II     209              NED
  8             Right foreleg   T2        PWT Grade II     205              NED
  8             Flank           T3        PNST Grade II    149              NED

(PWT): perivascular wall tumor; (U-SA): undifferentiated sarcoma; (HSA): hemangiosarcoma; (PNST): peripheral nerve sheat tumor; (FSA): fibrosarcoma; (CSA): chondrosarcoma; (LipoSA): liposarcoma; (NED): no evidence of disease; (\*): Days.

Discussion {#sec4}
==========

Our results provide valuable insight into long-term outcome of dogs with STS treated with combination adjuvant ECT. In STS surgery, clean resection margins remain the gold standard, with several studies claiming increased overall and disease-free survival times with wider surgical margins ([@ref10]; [@ref6]; [@ref7]). General orientation for canine STSs calls for en-block resection with 2--3 cm of lateral margins, and the inclusion of one fascial plane deep to the tumor bed ([@ref4]; [@ref3]; [@ref9]). However, this optimal surgical procedure is rarely accomplished with most canine sarcomas still being marginally excised ([@ref10]; [@ref6]; [@ref7]; [@ref3]). Recent clinical evidence suggests that increasing the extension of surgical excision is not enough to improve the treatment success for all STSs ([@ref3]). Moreover, beside the aggressiveness of surgical technique, other factors play a pivotal role in STSs control, including size, histotype, and histologic grade ([@ref14]; [@ref3]). Other management options include a combination of surgery plus radiotherapy and chemotherapy ([@ref8]; [@ref13]; [@ref18]; [@ref5]). Radiotherapy is currently the elective adjuvant treatment for incompletely excised solid tumors. However, it has some limitations: 1) availability of a radiation facility, 2) cost of the treatment, and 3) possibility of serious but non-life-threatening local complications such as wound dehiscence, self-trauma, and osteonecrosis of underlying bone ([@ref5]). ECT is an anticancer therapy that associates the systemic and/or local administration of chemotherapy agents with the delivery of permeabilizing electric pulses with specific amplitude, duration, and waveforms ([@ref25], [@ref26]). This strategy is helpful to increase the efficacy of lipophobic drugs that often have a narrow therapeutic index, thus minimizing patient toxicoses while maintaining adequate anticancer efficacy ([@ref24]). ECT has been described as a useful adjuvant therapy for the treatment of both feline and canine STSs \[Reviewed in [@ref25]\]. Regarding its application in STSs, ECT is almost exclusively used in an adjuvant modality since these neoplasms show a limited response to ECT alone ([@ref25]). Consequently, ECT has been adopted as an adjuvant therapy after surgical excision of STSs in several canine and feline studies ([@ref20], [@ref21], [@ref23]). In these studies, the chemotherapy agent (either bleomycin or cisplatin) was injected in the tumor bed. All these studies evidenced a clear clinical gain in terms of local control. In all these adjuvant studies, side effects were limited to local inflammation and occasional wound dehiscence, with the exception of a previously radiated cat that experienced a radiation recall ([@ref19], [@ref22], 2009, [@ref23]). This is the first report of a combined ECT approach in veterinary medicine with cisplatin and bleomycin. Systemic bleomycin administration increased the likelihoods of drug distribution in the deeper layers of the tumor bed, while the local injection of cisplatin was aimed at increasing ECT efficacy in the superficial layers. Our results show that this combination can improve the control of aggressive STS with limited side effects, even better than our previous published canine protocol. In terms of response, we have 86.6% of the treated subjects, still in remission at the time of writing compared to 50% of the previous study ([@ref19]). Furthermore, the estimated disease free interval in the current study is 859 d (median time not reached), while it was of 730 d in the previous study ([@ref19]). Moreover, we observed a greater disease-free interval for perivascular wall tumors compared to other STSs although this phenomenon was not statistically significant. Generally speaking, perivascular wall tumors are less prone to recurrence than other histotypes, especially if they are located in the extremities ([@ref28]). In particular, it has been underlined that for those neoplasms, size, grade (\>I), and location of the tumor were significant prognostic factors, while status of margins had only a clinically relevant hazard ratio ([@ref28]). In our patients cohort, the tumors we treated were mostly grade II or higher and had also a considerable size (T2 or T3) although most of the perivascular wall tumors (PWTs) were located in the extremities. This supports the increased local control obtained with ECT in our patients. Surgery remains the cornerstone for the treatment of STSs, being most of the time able to achieve local control by itself, especially for certain types such as the PWTs ([@ref27], [@ref23]; [@ref3]). In case of incomplete excision for tumors that are likely to recur, adjuvant therapies are advocated, and among them, ECT displays a reasonable ratio between cost and benefits, as also shown by the current literature ([@ref19], [@ref23]). In the future studies, we plan to increase the number of cases treated with this combination protocol and to expand the tumor histotypes analyzed, in order to confirm the data presented and to identify subgroups that are more responsive. In conclusion, our data suggest that ECT can be considered an additional adjuvant therapy to increase local control of canine STS. We propose to consider it an effective addition to the current anticancer strategies for STS in veterinary medicine.

![(A) Kaplan--Meyer curve showing the time to recurrence for 30 dogs with STS treated with adjuvant ECT. (B) Kaplan--Meyer curve showing the time to recurrence for dogs with peripheral wall tumors versus other sarcomas.](OpenVetJ-9-88-g002){#fig2}
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